OraLiva
OraLiva is an AI diagnostics company that provides a non-invasive brush biopsy test for early oral cancer detection, serving general dentists, dental specialists, and DSOs through a CLIA-certified lab and payer partnerships with Delta Dental plans.
- Company typePrivate
- Founded2023
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What OraLiva does
OraLiva is a privately held AI precision diagnostics company developing a non-invasive brush biopsy platform for early oral cancer and dysplasia detection. The company's core offering is the OraLiva Brush Biopsy test, in which dental providers collect a transepithelial cell sample chairside in under two minutes using a soft brush; samples are shipped to OraLiva's CLIA-certified laboratory in Durham, NC, where they are processed and analyzed on the proprietary ONC IN-CYT platform. That platform combines microfluidic cytomics-on-a-chip, automated multi-spectral fluorescence imaging, and deep-learning algorithms trained on more than 13 million single-cell images from a 999-patient NIH-supported study, producing a numerical risk score (the Oral Cancer Numerical Index, or OCNI) and a digital report returned within one to two weeks.
The commercial model is a transaction-fee laboratory diagnostic service: dental providers order the test, collect the sample, and are reimbursed under CDT D7288 by participating dental plans, while OraLiva bills the patient's medical insurance for the AI cytology analysis component. The go-to-market is sales-led, anchored by payer partnerships — most notably a multi-state commercial launch with Delta Dental of Michigan, Ohio, Indiana, and North Carolina beginning January 2026, with planned Year 2 expansion to Arkansas, Kentucky, New Mexico, and Tennessee. Target customers are general dentists, dental specialists (oral surgeons, periodontists, ENTs), and Dental Service Organizations (DSOs) seeking standardized, billable, chairside screening. Distribution is reinforced by CE programs, demo bookings, and a channel partnership with Henry Schein.
Beyond the current oral cancer indication, OraLiva is extending the platform via transfer learning into cervical, bladder, and anal cancers under NIH/NCI and NSF grants, and is developing a next-generation point-of-care device (ONC IN-CYT v2) toward FDA clearance. Total funding is approximately $5.5 million, comprising a $2.0 million oversubscribed seed round (October 2025) and $3.5 million in non-dilutive grants from NIH/NIDCR, NIH/NCI, and NSF during 2025. The company is led by CEO Spencer Price, Co-Founder & President Anna Grassini, and scientific founder Dr. John T. McDevitt (NYU McDevitt Lab), and remains in early commercialization with 1-10 employees.
OraLiva firmographics
Firmographics- Name
- OraLiva
- Legal name
- OraLiva, Inc.
- Website
- https://oraliva.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OraLiva is an AI diagnostics company that provides a non-invasive brush biopsy test for early oral cancer detection, serving general dentists, dental specialists, and DSOs through a CLIA-certified lab and payer partnerships with Delta Dental plans.
- Ownership category
- akta.pro rank
OraLiva industry classification
Industry- Product category
- Oral Cancer Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oral Cancer Screening (HLABAHAF)
- akta.pro secondary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where OraLiva is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
OraLiva business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Laboratory Diagnostic Testing Service: OraLiva collects brush biopsy samples from dental providers and processes them in its CLIA-certified laboratory in Durham, NC. The company bills patients' medical insurance for the analysis component. Dental providers are reimbursed under CDT D7288 (brush biopsy—transepithelial sample collection) by Delta Dental plans.
- CLIA Laboratory Services: Revenue generated from processing samples in the CLIA-certified laboratory, with billing to medical insurance for the AI cytology analysis.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels11 records
OraLiva product offering
Product offeringCore offering
OraLiva provides an AI-powered, non-invasive brush biopsy diagnostic test for early detection of oral cancer and dysplasia. Dental providers collect transepithelial cell samples chairside in under two minutes using a soft brush (no scalpel or anesthesia required), which are shipped to OraLiva's CLIA-certified laboratory in Durham, NC. Samples are processed through the proprietary ONC IN-CYT platform combining microfluidic cytomics-on-a-chip, automated multi-spectral fluorescence imaging, and deep-learning AI algorithms trained on 13 million+ single-cell images to generate a numerical Oral Cancer Numerical Index (OCNI) risk score delivered as a digital report within 1-2 weeks.
Product overview
OraLiva offers a unified product portfolio centered on AI-powered cytology diagnostics for early oral cancer detection. The core offering consists of the OraLiva Brush Biopsy test—a non-invasive, chairside oral cancer screening tool—powered by the proprietary ONC IN-CYT platform (now in version 2). The ONC IN-CYT platform serves as the analytical engine, combining microfluidic sample processing, automated fluorescence imaging, and deep-learning AI algorithms to generate the Oral Cancer Numerical Index (OCNI) risk score. The platform is initially launching with a focus on oral cancer detection, with roadmap expansion to lung, esophageal, colorectal, bladder, cervical, and anal cancers using cross-indication biomarker signatures. The system is designed for dental practices, specialists, and DSOs, with results delivered via secure digital portal within 1-2 weeks.
Differentiator
Problem solved
Functional benefit
Brands
- ONC IN-CYT: OraLiva's AI-powered cytology platform that combines microfluidic cytology collection, digital imaging, and artificial intelligence for clinically validated risk-stratified reports.
Products and services
- OraLiva Oral Cancer Test (Brush Biopsy) Non-invasive, chairside brush biopsy service for early oral cancer and dysplasia detection. Dental providers (general dentists, specialists, DSOs) collect transepithelial cell samples during routine exams; samples are analyzed in OraLiva's CLIA-certified laboratory using the ONC IN-CYT AI platform to deliver risk-stratified reports with a numerical OCNI score and actionable clinical recommendation. Billable under CDT D7288 (dental) and CPT 88112 (medical insurance for lab analysis).
- ONC IN-CYT Platform Scalable oncology diagnostics pipeline leveraging cross-indication biomarker cyto-signatures. Combines microfluidic sample processing, automated fluorescence imaging, and AI algorithms trained on 13M+ cell images for early cancer detection across epithelial tissues (oral, lung, esophageal, colorectal, bladder, anal, cervical). Operates as a CLIA-certified Laboratory Developed Test (LDT) in Durham, NC.
Quantifiable outcome
- 97% diagnostic accuracy, 94% sensitivity, 92% specificity for dysplasia and early oral cancer detection (Journal of Dental Research, 2021)
- +4 more outcomes
Companies that use OraLiva
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
OraLiva technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
OraLiva partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic, core and minor.
- Rovers Medical DevicesstrategicOraLiva has partnered with Rovers Medical Devices, a global leader in medical sampling devices, to utilize the Orcellex brush technology for OraLiva's AI-powered oral cytology test. The Orcellex brush is designed to collect high-quality transepithelial cellular samples, which are then analyzed using OraLiva's AI-driven analytical platform to identify cellular abnormalities associated with oral cancer and precancerous lesions.
- Delta Dental of Michigan, Delta Dental of Ohio, Delta Dental of Indiana, Delta Dental of North CarolinacoreDelta Dental plans have reaffirmed their commitment to preventive oral health with a multi-state commercial launch of OraLiva's AI-powered oral cancer test. The collaboration covers non-invasive cytology and AI risk-stratification to dentists across Michigan, Ohio, Indiana, and North Carolina in Year 1, with expansion to Arkansas, Kentucky, New Mexico, and Tennessee in Year 2. Delta Dental reimburses providers under CDT D7288 and offers CE modules on oral lesion recognition through DDMI's learning platforms.
- CareQuest Innovation PartnerscoreOraLiva was highlighted by CareQuest Innovation Partners in their SMILE Health program case study, recognizing the AI-powered brush biopsy platform for addressing late oral cancer detection. CareQuest Innovation Partners supports OraLiva's mission to bring lab-quality cytology into the dental chair through its innovation ecosystem.
- Henry ScheinminorStrategic partnership with Henry Schein mentioned in the CareQuest Innovation Partners case study as a channel partner supporting adoption and access at scale for OraLiva's technology.
- NYU College of Dentistry / McDevitt LabcoreOraLiva was founded out of the NYU School of Dentistry and the McDevitt Lab. The company's technology builds on over a decade of NIH-funded research at NYU, producing the largest oral lesion study to date. The NYU Entrepreneurial Institute and NYU Innovation Venture Fund provided funding and commercialization guidance, with the Innovation Venture Fund also participating as an investor in OraLiva's seed round.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
OraLiva competitors and assessment
Company assessmentDirect peers
- Forward Science: Forward Science manufactures OralID, a fluorescence-based oral cancer screening adjunct used by dental professionals. It competes with OraLiva for the same dental chairside screening use case, though via tissue fluorescence rather than cytological analysis.
- Envista Holdings (Identafi): Envista's dental portfolio includes the Identafi multi-spectral oral cancer screening device, which competes with OraLiva in the dental adjunctive screening category. Envista is a much larger dental products conglomerate, giving its screening offering broad commercial reach.
- CDx Diagnostics: CDx Diagnostics developed OralCDx, the original computer-assisted brush biopsy test for oral cancer detection. It is the most direct historical competitor to OraLiva's AI-powered brush biopsy, serving the same dental provider channel with a similar sample-collection workflow.
- DenMat (VELscope): DenMat distributes VELscope, one of the most widely deployed adjunctive oral cancer screening devices in dentistry. It competes directly with OraLiva for the dental-provider screening workflow, offering a lower-cost, light-based alternative to OraLiva's cytology approach.
Broad incumbents
- Guardant Health: Guardant Health is a publicly traded leader in liquid biopsy and oncology diagnostics. While OraLiva focuses on brush-based cytology rather than blood-based liquid biopsy, both companies operate AI-driven molecular diagnostics for cancer detection, and OraLiva's roadmap into multi-cancer screening overlaps with Guardant's strategic territory.
- Exact Sciences: Exact Sciences is a publicly traded cancer screening leader (Cologuard) that has expanded into multi-cancer early detection via the Thrive acquisition. Its cancer-screening franchise and AI-driven diagnostics platform make it a relevant broad incumbent comparable to OraLiva's cross-indication expansion thesis.
- Foundation Medicine: Foundation Medicine, a Roche subsidiary, is a leading molecular oncology diagnostics provider using genomic profiling to guide cancer care. It is a broad incumbent in AI-driven cancer diagnostics and represents the type of scaled, regulated diagnostic infrastructure OraLiva aspires to build across multiple cancer types.
Emerging players
- Tempus AI: Tempus combines AI with multi-modal data to deliver precision medicine diagnostics, including oncology applications. Its AI-first approach to clinical diagnostics parallels OraLiva's deep-learning strategy, though Tempus operates at a much larger scale and broader indication set.
- Delfi Diagnostics: Delfi Diagnostics is an AI-driven cancer detection company developing blood-based multi-cancer screening tests. Its use of machine learning on biological signals to detect cancer early positions it as a comparable emerging player to OraLiva's AI cytology approach.
- PathAI: PathAI applies deep learning to pathology diagnostics across multiple cancer types. Its AI-powered cellular and tissue analysis capabilities are technologically analogous to OraLiva's deep-learning cytology platform, making it a relevant emerging-player peer in the AI pathology space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OraLiva social profiles
Digital presenceOraLiva compliance and trust
Trust signalCompliance2 records
OraLiva financial estimates
Financial estimateRevenue estimate
Valuation estimate
OraLiva leadership team
Management profileNumber of profiles
Profiles10 records
OraLiva funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OraLiva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OraLiva
What does OraLiva do?
OraLiva provides an AI-powered, non-invasive brush biopsy diagnostic test for early detection of oral cancer and dysplasia. Dental providers collect transepithelial cell samples chairside in under two minutes using a soft brush (no scalpel or anesthesia required), which are shipped to OraLiva's CLIA-certified laboratory in Durham, NC. Samples are processed through the proprietary ONC IN-CYT platform combining microfluidic cytomics-on-a-chip, automated multi-spectral fluorescence imaging, and deep-learning AI algorithms trained on 13 million+ single-cell images to generate a numerical Oral Cancer Numerical Index (OCNI) risk score delivered as a digital report within 1-2 weeks.
Is OraLiva a public or private company?
OraLiva is a private company. It is classified as venture growth investor backed and is currently operating.
When was OraLiva founded?
OraLiva was founded in 2023. It employs 1 to 10 people.
Where is OraLiva based?
OraLiva is headquartered in New York, United States, in the North America region.
How does OraLiva make money?
Two revenue lines are on record. Laboratory Diagnostic Testing Service is the primary driver. The others are CLIA Laboratory Services.
Who are OraLiva's main competitors?
Direct peers on record are Forward Science, Envista Holdings (Identafi), CDx Diagnostics and DenMat (VELscope). Broad incumbents are Guardant Health, Exact Sciences and Foundation Medicine. Emerging players are Tempus AI, Delfi Diagnostics and PathAI.
Does OraLiva have an API?
No public API is recorded for OraLiva.
What industry is OraLiva in?
OraLiva's product category is Oral Cancer Diagnostics. Its primary akta.pro industry code is HLABAHAF, Oral Cancer Screening, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.